JP2014224759A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014224759A5 JP2014224759A5 JP2013104124A JP2013104124A JP2014224759A5 JP 2014224759 A5 JP2014224759 A5 JP 2014224759A5 JP 2013104124 A JP2013104124 A JP 2013104124A JP 2013104124 A JP2013104124 A JP 2013104124A JP 2014224759 A5 JP2014224759 A5 JP 2014224759A5
- Authority
- JP
- Japan
- Prior art keywords
- psychiatric
- neurological disorder
- biomarker
- free
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000012902 Nervous system disease Diseases 0.000 claims description 23
- 208000020016 psychiatric disease Diseases 0.000 claims description 23
- 239000000090 biomarker Substances 0.000 claims description 15
- 239000008280 blood Substances 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 6
- 238000012360 testing method Methods 0.000 claims description 6
- 238000010998 test method Methods 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 6
- 102000018358 immunoglobulin Human genes 0.000 claims 6
- 206010003805 Autism Diseases 0.000 claims 5
- 208000020706 Autistic disease Diseases 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 201000000980 schizophrenia Diseases 0.000 claims 5
- 239000000126 substance Substances 0.000 claims 3
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102000003777 Interleukin-1 beta Human genes 0.000 claims 1
- 108090000193 Interleukin-1 beta Proteins 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 102000004889 Interleukin-6 Human genes 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 238000003018 immunoassay Methods 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013104124A JP6205175B2 (ja) | 2013-05-16 | 2013-05-16 | 精神・神経疾患バイオマーカー |
| EP14797879.5A EP3002588B1 (en) | 2013-05-16 | 2014-03-18 | Use of a biomarker for diagnosing schizophrenia |
| US14/891,301 US10041954B2 (en) | 2013-05-16 | 2014-03-18 | Biomarker for psychiatric and neurological disorders |
| PCT/JP2014/057227 WO2014185145A1 (ja) | 2013-05-16 | 2014-03-18 | 精神・神経疾患バイオマーカー |
| US15/645,907 US20180120328A1 (en) | 2013-05-16 | 2017-07-10 | Biomarker for psychiatric and neurological disorders |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013104124A JP6205175B2 (ja) | 2013-05-16 | 2013-05-16 | 精神・神経疾患バイオマーカー |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014224759A JP2014224759A (ja) | 2014-12-04 |
| JP2014224759A5 true JP2014224759A5 (enExample) | 2016-07-28 |
| JP6205175B2 JP6205175B2 (ja) | 2017-10-04 |
Family
ID=51898130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013104124A Active JP6205175B2 (ja) | 2013-05-16 | 2013-05-16 | 精神・神経疾患バイオマーカー |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US10041954B2 (enExample) |
| EP (1) | EP3002588B1 (enExample) |
| JP (1) | JP6205175B2 (enExample) |
| WO (1) | WO2014185145A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6205175B2 (ja) | 2013-05-16 | 2017-10-04 | 株式会社Ｒｅｓｖｏ | 精神・神経疾患バイオマーカー |
| JP7301327B2 (ja) * | 2017-11-24 | 2023-07-03 | 学校法人 京都産業大学 | マウスのうつ及び／又は不安症バイオマーカー |
| JP6737995B2 (ja) * | 2018-11-29 | 2020-08-12 | 株式会社Ｒｅｓｖｏ | 精神疾患発症危険状態の診断用バイオマーカー |
| GB202000634D0 (en) * | 2020-01-15 | 2020-02-26 | Nat Institute Of Mental Health | Diagnostic method |
| JP6817666B2 (ja) * | 2020-06-24 | 2021-01-20 | 株式会社Ｒｅｓｖｏ | 精神疾患発症危険状態の診断用バイオマーカー |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE243747T1 (de) * | 1991-07-15 | 2003-07-15 | Wellcome Found | Herstellung von antikörpern |
| US20060191026A1 (en) | 2005-02-18 | 2006-08-24 | Origen Therapeutics, Inc. | Tissue specific expression of antibodies in chickens |
| EP2322203A3 (en) | 2002-10-29 | 2011-07-27 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| BRPI0707958B8 (pt) * | 2006-02-17 | 2021-07-27 | Sekiyama Atsuo | composição e kit para testar condições mentais por uma análise de regressão logística e método de medição de condições mentais |
| GB0724735D0 (en) | 2007-12-19 | 2008-01-30 | Psynova Neurotech Ltd | Methods and biomarkers for diagnosing and monitoring psychotic disorders |
| US20120135542A1 (en) * | 2009-06-05 | 2012-05-31 | Mayo Foundation For Medical Education And Research | Methods and materials for diagnosing light chain amyloidosis |
| GB0915736D0 (en) * | 2009-09-09 | 2009-10-07 | Cambridge Entpr Ltd | Biomarkers |
| GB201008340D0 (en) * | 2010-05-19 | 2010-07-07 | Cambridge Entpr Ltd | Biomarkers |
| JP5641471B2 (ja) | 2010-06-29 | 2014-12-17 | 国立大学法人名古屋大学 | 統合失調症マーカー及びその利用 |
| CN103370624A (zh) | 2010-12-06 | 2013-10-23 | 里奇诊断学股份有限公司 | 监控神经精神疾病治疗的生物标记 |
| US20120238837A1 (en) * | 2011-03-16 | 2012-09-20 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | System, devices, and methods for real-time monitoring of cerebrospinal fluid for markers of progressive conditions |
| JP6205175B2 (ja) | 2013-05-16 | 2017-10-04 | 株式会社Ｒｅｓｖｏ | 精神・神経疾患バイオマーカー |
-
2013
- 2013-05-16 JP JP2013104124A patent/JP6205175B2/ja active Active
-
2014
- 2014-03-18 WO PCT/JP2014/057227 patent/WO2014185145A1/ja not_active Ceased
- 2014-03-18 EP EP14797879.5A patent/EP3002588B1/en not_active Not-in-force
- 2014-03-18 US US14/891,301 patent/US10041954B2/en active Active
-
2017
- 2017-07-10 US US15/645,907 patent/US20180120328A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lee et al. | Aptamer-based sandwich assay and its clinical outlooks for detecting lipocalin-2 in hepatocellular carcinoma (HCC) | |
| JP6430413B2 (ja) | アルツハイマー病の診断のための方法と組成物 | |
| EP3504553B1 (en) | System and method for analysis of biological data | |
| US10247730B2 (en) | Method for determining acute respiratory distress syndrome (ARDS) related biomarkers, a method to monitor the development and treatment of ARDS in a patient | |
| JP6082767B2 (ja) | 化学発光タンパク質チップ測定方法及びそれに用いられる試薬キット | |
| Lee et al. | Multiplex giant magnetoresistive biosensor microarrays identify interferon-associated autoantibodies in systemic lupus erythematosus | |
| Malekzadeh et al. | Challenges in multi-plex and mono-plex platforms for the discovery of inflammatory profiles in neurodegenerative diseases | |
| EP4045912A1 (en) | Apparatuses and methods for detection of pancreatic cancer | |
| Kruse et al. | Development of electrochemiluminescence-based singleplex and multiplex assays for the quantification of α-synuclein and other proteins in cerebrospinal fluid | |
| JP6934508B2 (ja) | 心不全におけるスタチン治療階層化のためのマーカー | |
| Yang et al. | Development and evaluation of up-converting phosphor technology-based lateral flow assay for quantitative detection of NT-proBNP in blood | |
| WO2011136080A1 (ja) | 動脈硬化の評価法 | |
| EP3445782A2 (en) | Compositions and methods related to k180 dimethylated h1.0 protein | |
| JP2014224759A5 (enExample) | ||
| Valera et al. | Development and validation of an immunosensor for monocyte chemotactic protein 1 using a silicon photonic microring resonator biosensing platform | |
| CN103823058B (zh) | 血清中抗原类蛋白的化学发光蛋白芯片方法和试剂盒 | |
| Tan et al. | Rapid and quantitative detection of COVID-19 markers in micro-liter sized samples | |
| TWI655433B (zh) | 川崎氏症之診斷與治療 | |
| JP6205175B2 (ja) | 精神・神経疾患バイオマーカー | |
| WO2015019979A1 (ja) | 統合失調症に関するバイオマーカー | |
| Nguyen et al. | Capillary electrophoresis-laser-induced fluorescence (CE-LIF)-based immunoassay for quantifying antibodies against cyclic citrullinated peptides | |
| Kruse et al. | Validation of electrochemiluminescence assays for highly sensitive and reproducible quantification of α-synuclein in cerebrospinal fluid | |
| Wang et al. | Determination of plasma β-amyloids by rolling circle amplification chemiluminescent immunoassay for noninvasive diagnosis of Alzheimer’s disease | |
| Ourradi et al. | Development and validation of novel biomarker assays for osteoarthritis | |
| CN111562390A (zh) | 一种神经精神性狼疮的诊断标志物及其检测试剂盒 |